Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
brodalumab
palmoplantar psoriasis
plaque psoriasis
real-world evidence
scalp psoriasis
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
26
03
2023
received:
07
11
2022
accepted:
26
06
2023
medline:
10
11
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
The data in clinical practice regarding the effectiveness and safety of brodalumab in psoriasis are scarce, especially at scalp and palmoplantar locations. The main objective was the percentage of patients achieving absolute PASI ≤3/ ≤1/ =0 for plaque psoriasis and the percentage of patients achieving an IGA 0-1/IGA 0 for the special locations at Week 52 of treatment. Observational retrospective multicentre study in 28 Spanish Hospitals that included adult patients with plaque psoriasis treated with brodalumab, from September 2018 until March 2021. A total of 200 patients were included. The mean baseline PASI was 10.97 (±6.28) with a mean basal scalp (n = 58) and palmoplantar (n = 40) IGA of 2.10 (±0.97) and 2.15 (±1.26), respectively. At Week 52, 93.98%/75.90%/68.67% of patients reached an absolute PASI ≤3/ ≤1/ =0 in plaque psoriasis (n = 83), with a percentage of patients achieving scalp (n = 27) and palmoplantar (n = 19) IGA 0-1/IGA 0 of 96.3%/88.9% and 100%/88.9%, respectively. Fifteen per cent of patients reported any adverse events with candidiasis being the most reported (6%), but only 6% of the adverse events required the withdrawal. Brodalumab demonstrated high PASI and IGA responses and was well tolerated in clinical practice in plaque, scalp and palmoplantar psoriasis.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
The data in clinical practice regarding the effectiveness and safety of brodalumab in psoriasis are scarce, especially at scalp and palmoplantar locations. The main objective was the percentage of patients achieving absolute PASI ≤3/ ≤1/ =0 for plaque psoriasis and the percentage of patients achieving an IGA 0-1/IGA 0 for the special locations at Week 52 of treatment.
PATIENTS AND METHODS
METHODS
Observational retrospective multicentre study in 28 Spanish Hospitals that included adult patients with plaque psoriasis treated with brodalumab, from September 2018 until March 2021.
RESULTS
RESULTS
A total of 200 patients were included. The mean baseline PASI was 10.97 (±6.28) with a mean basal scalp (n = 58) and palmoplantar (n = 40) IGA of 2.10 (±0.97) and 2.15 (±1.26), respectively. At Week 52, 93.98%/75.90%/68.67% of patients reached an absolute PASI ≤3/ ≤1/ =0 in plaque psoriasis (n = 83), with a percentage of patients achieving scalp (n = 27) and palmoplantar (n = 19) IGA 0-1/IGA 0 of 96.3%/88.9% and 100%/88.9%, respectively. Fifteen per cent of patients reported any adverse events with candidiasis being the most reported (6%), but only 6% of the adverse events required the withdrawal.
CONCLUSIONS
CONCLUSIONS
Brodalumab demonstrated high PASI and IGA responses and was well tolerated in clinical practice in plaque, scalp and palmoplantar psoriasis.
Substances chimiques
brodalumab
6ZA31Y954Z
Antibodies, Monoclonal
0
Immunoglobulin A
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e317-e326Informations de copyright
© 2023 The Australasian College of Dermatologists.
Références
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218-224. https://doi.org/10.1016/j.jaad.2008.09.022
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60:394-401. https://doi.org/10.1016/j.jaad.2008.10.062
Ferrándiz C, Bordas X, García-Patos V, Puig S, Pujol R, Smandía A. Prevalence of psoriasis in Spain (Epiderma project: phase I). J Eur Acad Dermatol Venereol. 2001;15:20-23. https://doi.org/10.1046/j.1468-3083.2001.00191.x
Oulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570. https://doi.org/10.7573/dic.212570
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-1328. https://doi.org/10.1056/NEJMoa1503824
Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273-286. https://doi.org/10.1111/bjd.14493
Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2022;33:261-265. https://doi.org/10.1080/09546634.2020.1749546
Mason KJ, Barker J, Smith C, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154:581-588. https://doi.org/10.1001/jamadermatol.2018.0183
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, et al. Risk of serious adverse events associated with biologicand nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148:463-470. https://doi.org/10.1001/archdermatol.2011.2768
Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network metaanalysis. J Dermatol Sci. 2020;99:53-61. https://doi.org/10.1016/j.jdermsci.2020.06.003
Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a metaanalysis. JAMA Dermatol. 2020;156:258-269. https://doi.org/10.1001/jamadermatol.2019.4029
Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. Dermatol Ther. 2020;10:73-86. https://doi.org/10.1007/s13555-019-00337-y
Fargnoli MC, Esposito M, Dapavo P, Parodi A, Rossi M, Tiberio R, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35:693-700. https://doi.org/10.1111/jdv.16931
Galluzzo M, Caldarola G, de Simone C, Bernardini N, Moretta G, Pallotta S, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21:1299-1310. https://doi.org/10.1080/14712598.2021.1941862
Tampouratzi E, Papakonstantis M, Katsantonis J, Sidiropoulos T, Delli F, Efthymiadis K, et al. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: experience from clinical practice of four tertiary hospitals. Dermatol Ther. 2022;35:e15532. https://doi.org/10.1111/dth.15532
Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;27:e15667. Online ahead of print. https://doi.org/10.1111/dth.15667
Kojanova M, Hugo J, Velackova B, Cetkovska P, Fialova J, Dolezal T, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors- brodalumab, ixekizumab, and secukinumab: real-world data from The Czech Republic BIOREP registry. J Dermatolog Treat. 2022;33:2827-2837. https://doi.org/10.1080/09546634.2022.2082354
Lebwohl M, Menter A, Lain E, Han G, Jacobson A. Long-term skin clearance with Brodalumab in patients with psoriasis and inadequate response to prior biologics. J Drugs Dermatol. 2022;21:354-370. https://doi.org/10.36849/JDD.6743
Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A. Narrative review of the emerging therapeutic role of Brodalumab in difficult-to-treat psoriasis. Dermatol Ther (Heidelb). 2022;12:1289-1302. https://doi.org/10.1007/s13555-022-00746-6
Rompoti N, Katsimbri P, Kokkalis G, Boumpas D, Ikonomidis I, Theodoropoulos K, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019;32:e13006. https://doi.org/10.1111/dth.13006
Reolid A, Armesto S, Sahuquillo-Torralba A, Torres T, Feltes R, Vilarrasa E, et al. Secukinumab is effective and safe in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. J Am Acad Dermatol. 2022;87:705-709. https://doi.org/10.1016/j.jaad.2022.05.047
Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group. Brodalumab, a human antiinterleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81:44-52. https://doi.org/10.1016/j.jdermsci.2015.10.009
Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47-62. https://doi.org/10.1111/bjd.15015
Lebwohl M, Leonardi C, Armstrong A, Rawnsley N, Alexander B, Goehring E Jr, et al. Three-year U.S. pharmacovigilance report of brodalumab. Dermatol Ther. 2022;35:e15664. https://doi.org/10.1111/dth.15105
Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34:1449-1456. https://doi.org/10.1111/jdv.16254
Burisch J, Eigner W, Schreiber S, Aletaha D, Weninger W, Trauner M, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PloS One. 2020;15:e0233781. https://doi.org/10.1371/journal.pone.0233781
Penso L, Bergqvist C, Meyer A, Herlemont P, Weill A, Zureik M, et al. Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis/ankylosing spondylitis initiating interleukin-17 inhibitors: a nationwide population-based study using the French national health data system. Arthritis Rheumatol. 2022;74:244-252. https://doi.org/10.1002/art.41923
Caron B, Jouzeau JY, Miossec P, Petitpain N, Gillet P, Netter P, et al. Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opin Drug Saf. 2022;21:223-239. https://doi.org/10.1080/14740338.2021.1960981
Petitpain N, D'Amico F, Yelehe-Okouma M, Jouzeau JY, Netter P, Peyrin-Biroulet L, et al. IL-17 inhibitors and inflammatory bowel diseases: a Postmarketing study in Vigibase. Clin Pharmacol Ther. 2021;110:159-168. https://doi.org/10.1002/cpt.2155
Mease PJ, Helliwell PS, Hjuler KF, Raymond K, McInnes I. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021;80:185-193. https://doi.org/10.1136/annrheumdis-2019-216835
McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022;8:e002074. https://doi.org/10.1136/rmdopen-2021-002074